Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | NOS1 | P29475 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 3/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 2/20 | 0.45 |
| ▸ | CTSV | O60911 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30235066 | 1.00 | MAPT (0.61) | MAPTHPGDCA12CA9NOS1 | |
| SCHEMBL11145798 | 0.90 | MAPT (0.58) | MAPTHPGDCA12CA9NOS1 | |
| SCHEMBL26630251 | 0.88 | NOS1 (0.72) | MAPTHPGDCA12CA9NOS1 | |
| SCHEMBL2860178 | 0.87 | MAPT (0.50) | MAPTHPGDCA12CA9NOS1 | |
| SCHEMBL12193486 | 0.81 | MAPT (0.63) | MAPTHPGDCA12CA9NOS1 | |
| SCHEMBL757425 | 0.81 | MAPT (0.63) | MAPTHPGDCA12CA9NOS1 | |
| SCHEMBL4057244 | 0.81 | PARP1 (0.53) | MAPTHPGDCA12CA9NOS1 | |
| SCHEMBL4262245 | 0.81 | PARP1 (0.49) | MAPTHPGDCA12CA9NOS1 | |
| SCHEMBL3370857 | 0.80 | MAPT (0.61) | MAPTHPGDCA12CA9NOS1 | |
| SCHEMBL760614 | 0.80 | MAPT (0.61) | MAPTHPGDCA12CA9NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103570624-B | The synthesis technique of 3-bromo-5-nitro-1H-indazole | 安徽世华化工有限公司 | 2016-07-06 | — | — | CN | claimed |
| CN-103570624-A | Synthesis process of 3-bromo-5-nitro-1H-indazole | ANHUI SHIHUA CHEMICAL CO LTD | 2014-02-12 | — | — | CN | claimed |
| US-20260137684-A1 | ROCK2 Inhibitors And Uses Thereof | RESTOR PHARMACEUTICALS (US) | 2026-05-21 | — | — | US | disclosed |
| CN-119019333-B | Indazole-pyrazole skeleton compound and application thereof | 中国药科大学 | 2026-05-19 | — | — | CN | disclosed |
| US-12473294-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | DONG-A ST CO., LTD. (KR) | 2025-09-11 | — | — | US | disclosed |
| CN-119894878-A | Aromatic amide derivative and preparation method and application thereof | 浙江海正药业股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| EP-4514780-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | Dong-A ST Co., Ltd. (KR) | 2025-03-05 | — | — | EP | disclosed |
| CN-119019333-A | Indazole-pyrazole skeleton compound and application thereof | 中国药科大学 | 2024-11-26 | — | — | CN | disclosed |
| CN-118976029-A | Pharmaceutical composition for preventing or treating parkinson's disease or nonalcoholic steatohepatitis | 韩国化学研究院 | 2024-11-19 | — | — | CN | disclosed |
| US-20240270698-A2 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2024-08-15 | — | — | US | disclosed |
| EP-1343499-A2 | HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2003064397-A1 | INDAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2003-08-07 | — | — | WO | disclosed |
| EP-1313711-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-05-28 | — | — | EP | disclosed |
| WO-2003040109-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| WO-2002062290-A2 | HETEROCYCLIC SUBSTITUTED 2-METHYL-BENZIMIDAZOLE ANTIVIRAL AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-15 | — | — | WO | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
| US-20020099208-A1 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-25 | — | — | US | disclosed |
| WO-2002010137-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099208-A1 | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents | MAVS, ZC3HAV1, EIF2AK2 | MAPT 4716/4885HPGD 3534/4885CA12 3585/4885 |
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | TEAD1, TEAD2, TEAD3 | MAPT 34/4885HPGD 135/4885CA12 1895/4885 |
| US-20240270698-A2 | NOVEL PYRIMIDINE DERIVATIVE AND USE THEREOF | LRRK2, PFKL, PDK3 | MAPT 405/4885HPGD 2867/4885CA12 4885/4885 |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | MAPT 1000/4885HPGD 1197/4885CA12 4852/4885 |
| US-12473294-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | MAPT 673/4885HPGD 4196/4885CA12 4713/4885 |
| US-20260137684-A1 | ROCK2 Inhibitors And Uses Thereof | ROCK2, ROCK1, RHOA | MAPT 3785/4885HPGD 1076/4885CA12 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.